Nawaz Shaik Sarfaraz, Siddiqui Khalid
Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Cytokine X. 2022 Jan 22;4(1):100064. doi: 10.1016/j.cytox.2022.100064. eCollection 2022 Mar.
Metabolic syndrome (MetS) is a multifactorial disease characterized by metabolic abnormalities. Plasminogen activator inhibitor-1(PAI-1) is a key factor of the fibrinolysis its expression is elevated in insulin resistance, obesity, and MetS. In addition, an adiponectin produced by adipocytes is also key factor in MetS. This study aimed to investigate the relationship between PAI-1, adiponectin levels in MetS.
A total of 379 subjects were analyse in this cross-sectional study. MetS was defined by NCEP ATP-III criteria. Anthropometric, fasting blood glucose, HbA1c, total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, PAI-1, and adiponectin were measured.
PAI-1 levels were higher in MetS compared with non-MetS. In addition, adiponectin levels were significantly lower in MetS compared to non-MetS. Furthermore, increased level of PAI-1 corresponds with increase in prevalence of MetS. PAI-1 levels were significantly associated with MetS (OR = 2.51, CI = 1.23 - 5.14; p = 0.039).
PAI-1 increases the risk of MetS. PAI-1 and adiponectin regulation is useful in assesing the presence and severity of MetS. Further pharmacological targeting of PAI-1 studies are necessary for MetS management.
代谢综合征（MetS）是一种以代谢异常为特征的多因素疾病。纤溶酶原激活物抑制剂-1（PAI-1）是纤维蛋白溶解的关键因素，其在胰岛素抵抗、肥胖和代谢综合征中表达升高。此外，脂肪细胞产生的脂联素也是代谢综合征的关键因素。本研究旨在探讨代谢综合征中PAI-1、脂联素水平之间的关系。
本横断面研究共分析了379名受试者。代谢综合征根据美国国家胆固醇教育计划成人治疗组第三次报告（NCEP ATP-III）标准定义。测量了人体测量指标、空腹血糖、糖化血红蛋白、总胆固醇、高密度脂蛋白、低密度脂蛋白、甘油三酯、PAI-1和脂联素。
与非代谢综合征患者相比，代谢综合征患者的PAI-1水平更高。此外，与非代谢综合征患者相比，代谢综合征患者的脂联素水平显著更低。此外，PAI-1水平升高与代谢综合征患病率增加相对应。PAI-1水平与代谢综合征显著相关（比值比=2.51，可信区间=1.23 - 5.14；p=0.039）。
PAI-1增加代谢综合征风险。PAI-1和脂联素调节有助于评估代谢综合征的存在和严重程度。进一步针对PAI-1的药理学靶向研究对于代谢综合征的管理是必要的。
